GI-5005 THERAPEUTIC VACCINE PLUS PEG-IFN/RIBAVIRIN IMPROVES SUSTAINED VIROLOGIC RESPONSE VERSUS PEG-IFN/RIBAVIRIN IN PRIOR NON-RESPONDERS WITH GENOTYPE 1 CHRONIC HCV INFECTION

被引:0
|
作者
Pockros, Paul [1 ]
Jacobson, Ira [2 ]
Boyer, Thomas D. [3 ]
Schiff, Eugene R. [4 ]
Everson, Gregory T. [5 ]
Lee, William M. [6 ]
Vierling, John M. [7 ,8 ]
Lawitz, Eric [9 ]
Kugelmas, Marcelo [10 ,11 ]
Tsai, Naoky [12 ]
Shiffman, Mitchell L. [13 ]
Brown, Robert S. [14 ]
Armstrong, Brian R. [15 ]
Mattson, Alicia [16 ]
Rodell, Timothy C. [16 ]
Apelian, David [16 ]
机构
[1] Scripps Clin, La Jolla, CA 92037 USA
[2] Weill Cornell Med Coll, Ctr Study Hepatitis C, New York, NY USA
[3] Univ Arizona, Coll Med, Dept Med, Tucson, AZ USA
[4] Univ Miami, Sch Med, Ctr Liver Dis, Miami, FL USA
[5] Univ Colorado Denver, Dept Med, Aurora, CO USA
[6] Univ Texas SW Med Ctr Dallas, Dept Internal Med, Dallas, TX 75390 USA
[7] Baylor Coll Med, Dept Med & Surg, Houston, TX 77030 USA
[8] St Lukes Episcopal Hosp, Houston, TX 77030 USA
[9] Alamo Med Res, San Antonio, TX USA
[10] PC, S Denver Gastroenterol, Englewood, CO USA
[11] Swedish Med Ctr, Ctr Dis Liver & Pancreas, Englewood, CO 80110 USA
[12] Univ Hawaii, Honolulu, HI 96822 USA
[13] Liver Inst Virginia, Newport News, VA USA
[14] Columbia Univ, Coll Phys & Surg, New York, NY USA
[15] QST Consultat, Allendale, MI USA
[16] Globelmmune, Louisville, CO USA
关键词
D O I
暂无
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
LB-6
引用
收藏
页码:404A / 405A
页数:2
相关论文
共 50 条
  • [1] GI-5005 THERAPEUTIC VACCINE PLUS PEG-IFN/RIBAVIRIN IMPROVES END OF TREATMENT RESPONSE AT 48 WEEKS VERSUS PEG-IFN/RIBAVIRIN IN NAIVE GENOTYPE 1 CHRONIC HCV PATIENTS
    McHutchison, John G.
    Jacobson, Ira M.
    Boyer, Thomas D.
    Schiff, Eugene R.
    Everson, Gregory T.
    Lee, William M.
    Pockros, Paul
    Chasen, Richard M.
    Vierling, John M.
    Lawitz, Eric
    Kugelmas, Marcelo
    Tsai, Naoky
    Armstrong, Brian R.
    Rodell, Timothy C.
    Apelian, David
    HEPATOLOGY, 2009, 50 (06) : 9A - 10A
  • [2] GI-5005 IMMUNOTHERAPY PLUS PEG-IFN/RIBAVIRIN VERSUS PEG-IFN/RIBAVIRIN IN GENOTYPE 1 CHRONIC HCV SUBJECTS; PRELIMINARY PHASE 2 EVR ANALYSES
    Lawitz, E. J.
    Boyer, T. D.
    Everson, G. T.
    Jacobson, I. M.
    Lee, W.
    McHutchison, J. G.
    Pockros, P. J.
    Shiffman, M. L.
    Vierling, J. M.
    Cruickshank, S.
    Rodell, T. C.
    Apelian, D.
    JOURNAL OF HEPATOLOGY, 2009, 50 : S230 - S231
  • [3] GI-5005 THERAPEUTIC VACCINE PLUS PEG-IFN/RIBAVIRIN IMPROVES BIOPSY NECRO-INFLAMMATORY SCORES AND ALT NORMALIZATION AT 48 WEEKS VERSUS PEG-IFN/RIBAVIRIN IN GENOTYPE 1 CHRONIC HCV PATIENTS
    McHutchison, J. G.
    Goodman, Z. D.
    Everson, G. T.
    Jacobson, I. M.
    Boyer, T. D.
    Schiff, E. R.
    Lee, W. M.
    Chasen, R. M.
    Vierling, J. M.
    Lawitz, E. J.
    Kugelmas, M.
    Tsai, N. C.
    Buynak, R. J.
    Sheikh, A. M.
    Armstrong, B.
    Rodell, T. C.
    Apelian, D.
    JOURNAL OF HEPATOLOGY, 2010, 52 : S116 - S116
  • [4] GI-5005 THERAPEUTIC VACCINE PLUS PEG-IFN/RIBAVIRIN SIGNIFICANTLY IMPROVES VIROLOGIC RESPONSE AND ALT NORMALIZATION AT END-OF-TREATMENT AND IMPROVES SVR24 COMPARED TO PEG-IFN/RIBAVIRIN IN GENOTYPE-1 CHRONIC HCV PATIENTS
    Jacobson, I. M.
    McHutchison, J. G.
    Boyer, T. D.
    Schiff, E. R.
    Everson, G. T.
    Pockros, P. J.
    Chasen, R. M.
    Vierling, J. M.
    Lawitz, E. J.
    Kugelmas, M.
    Tsai, N. C.
    Shiffman, M. L.
    Buynak, R. J.
    Sheikh, A. M.
    Armstrong, B.
    Rodell, T. C.
    Apelian, D.
    JOURNAL OF HEPATOLOGY, 2010, 52 : S465 - S466
  • [5] GI-5005 Therapeutic Vaccine Enhances Virologic Clearance By Peg-IFN/Ribavirin In Naive HCV Genotype 1 Patients With IL28B Genotype T/T
    Shiffman, Mitchell L.
    Muir, Andrew J.
    Vierling, John M.
    Gordon, Stuart C.
    Kugelmas, Marcelo
    Wu, George Y.
    Nguyen, Tuan T.
    Balart, Luis A.
    McHutchison, John G.
    Armstrong, Brian R.
    Mann, Derrick L.
    Guo, Zhimin
    King, Thomas H.
    Ferraro, John
    Mattson, Alicia
    Rodell, Timothy C.
    Apelian, David
    HEPATOLOGY, 2012, 56 : 570A - 571A
  • [6] PHARMACOGENOMIC ANALYSIS REVEALS IMPROVED VIROLOGIC RESPONSE IN ALL IL-28B GENOTYPES IN NAIVE GENOTYPE 1 CHRONIC HCV PATIENTS TREATED WITH GI-5005 THERAPEUTIC VACCINE PLUS PEG-IFN/RIBAVIRIN
    McHutchison, J. G.
    Thompson, A. J.
    Jacobson, I. M.
    Boyer, T. D.
    Schiff, E. R.
    Everson, G. T.
    Vierling, J. M.
    Shiffman, M. L.
    Brown, R. S.
    Di Bisceglie, A. M.
    Gordon, S. C.
    Lee, W. M.
    Guo, Z.
    King, T. H.
    Armstrong, B.
    Rodell, T. C.
    Apelian, D.
    JOURNAL OF HEPATOLOGY, 2010, 52 : S457 - S457
  • [7] Reducing Peg-IFN doses causes later virologic response or no response in HCV genotype 1 patients treated with Peg-IFN alfa-2b plus ribavirin
    Oze, Tsugiko
    Hiramatsu, Naoki
    Song, Changho
    Yakushijin, Takayuki
    Iio, Sadaharu
    Doi, Yoshinobu
    Oshita, Masahide
    Hagiwara, Hideki
    Mita, Eiji
    Ito, Toshifumi
    Inui, Yoshiaki
    Hijioka, Taizo
    Tamura, Shinji
    Yoshihara, Harumasa
    Inoue, Atsuo
    Imai, Yasuharu
    Hayashi, Eijiro
    Kato, Michio
    Miyazaki, Masanori
    Hosui, Atsushi
    Miyagi, Takuya
    Yoshida, Yuichi
    Tatsumi, Tomohide
    Kiso, Shinichi
    Kanto, Tatsuya
    Kasahara, Akinori
    Hayashi, Norio
    Takehara, Tetsuo
    JOURNAL OF GASTROENTEROLOGY, 2012, 47 (03) : 334 - 342
  • [8] Reducing Peg-IFN doses causes later virologic response or no response in HCV genotype 1 patients treated with Peg-IFN alfa-2b plus ribavirin
    Tsugiko Oze
    Naoki Hiramatsu
    Changho Song
    Takayuki Yakushijin
    Sadaharu Iio
    Yoshinobu Doi
    Masahide Oshita
    Hideki Hagiwara
    Eiji Mita
    Toshifumi Ito
    Yoshiaki Inui
    Taizo Hijioka
    Shinji Tamura
    Harumasa Yoshihara
    Atsuo Inoue
    Yasuharu Imai
    Eijiro Hayashi
    Michio Kato
    Masanori Miyazaki
    Atsushi Hosui
    Takuya Miyagi
    Yuichi Yoshida
    Tomohide Tatsumi
    Shinichi Kiso
    Tatsuya Kanto
    Akinori Kasahara
    Norio Hayashi
    Tetsuo Takehara
    Journal of Gastroenterology, 2012, 47 : 334 - 342
  • [9] Endogenous IFNγ in chronic HCV genotype 4 patients treated with PEG-IFNα and ribavirin
    Sadeq, Refaat
    Mohtady, Heba
    Al Badawy, Nissreen
    Ibrahim, Salwa
    Omar, Abdul Rahman
    Husseiny, Mohamed I.
    El Zowalaty, Mohamed
    JOURNAL OF INFECTION IN DEVELOPING COUNTRIES, 2013, 7 (11): : 859 - 867
  • [10] HEPATIC PRR SIGNALING GENE EXPRESSION SHOWS DIFFERENTIAL RESPONSE TO HCV REPLICATION IN RESPONDERS AND NON-RESPONDERS TO PEG-IFN PLUS RIBAVIRIN
    Yuki, Nobukazu
    Matsumoto, Shinji
    Kato, Michio
    Yamaguchi, Toshikazu
    HEPATOLOGY, 2009, 50 (04) : 679A - 679A